<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37256149</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>B cell activation via immunometabolism in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1155421</StartPage><MedlinePgn>1155421</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1155421</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1155421</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease involving multiple organs in which B cells perform important functions such as antibody and cytokine production and antigen presentation. B cells are activated and differentiated by the primary B cell receptor, co-stimulatory molecule signals-such as CD40/CD40L-, the Toll-like receptors 7,9, and various cytokine signals. The importance of immunometabolism in the activation, differentiation, and exerting functions of B cells and other immune cells has been widely reported in recent years. However, the regulatory mechanism of immunometabolism in B cells and its involvement in SLE pathogenesis remain elusive. Similarly, the importance of the PI3K-Akt-mTOR signaling pathway, glycolytic system, and oxidative phosphorylation has been demonstrated in the mechanisms of B cell immunometabolic activation, mainly in mouse studies. However, the activation of the mTOR pathway in B cells in patients with SLE, the induction of plasmablast differentiation through metabolic and transcription factor regulation by mTOR, and the involvement of this phenomenon in SLE pathogenesis are unclear. In our studies using activated B cells derived from healthy donors and from patients with SLE, we observed that methionine, an essential amino acid, is important for mTORC1 activation. Further, we observed that splenic tyrosine kinase and mTORC1 activation synergistically induce EZH2 expression and plasmablasts by suppressing BACH2 expression through epigenomic modification. Additionally, we identified another mechanism by which the glutaminolysis-induced enhancement of mitochondrial function promotes plasmablast differentiation in SLE. In this review, we focused on the SLE exacerbation mechanisms related to the activation of immune cells-especially B cells-and immunometabolism and reported the latest findings in the field.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Iwata, Hajime Sumikawa and Tanaka.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajime Sumikawa</LastName><ForeName>Maiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Yoshiya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>147205-72-9</RegistryNumber><NameOfSubstance UI="D023201">CD40 Ligand</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="Y">Phosphatidylinositol 3-Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023201" MajorTopicYN="N">CD40 Ligand</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-cell</Keyword><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">glutaminolysis</Keyword><Keyword MajorTopicYN="N">immunometabolism</Keyword><Keyword MajorTopicYN="N">mitochondria</Keyword></KeywordList><CoiStatement>YT has received speaking fees and/or honoraria from Daiichi-Sankyo, Eli Lilly, Novartis, YL Biologics, Bristol-Myers, Eisai, Chugai, Abbvie, Astellas, Pfizer, Sanofi, Asahi-kasei, GlaxoSmithKline, Mitsubishi-Tanabe, Gilead, Janssen, research grants from Abbvie, Mitsubishi-Tanabe, Chugai, Asahi-Kasei, Eisai, Takeda, and Daiichi-Sankyo and consultant fee from Eli Lilly, Daiichi-Sankyo, Taisho, Ayumi, Sanofi, GlaxoSmithKline, and Abbvie. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>13</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>10</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37256149</ArticleId><ArticleId IdType="pmc">PMC10225689</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1155421</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch A, et al. . HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis (2010) 69(1):305&#x2013;8. doi:&#xa0;10.1136/ard.2008.096495</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.096495</ArticleId><ArticleId IdType="pubmed">19196727</ArticleId></ArticleIdList></Reference><Reference><Citation>Tipton CM, Fucile CF, Darce J, Chida A, Ichikawa T, Gregoretti I, et al. . Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol (2015) 16(7):755&#x2013;65. doi:&#xa0;10.1038/ni.3175</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3175</ArticleId><ArticleId IdType="pmc">PMC4512288</ArticleId><ArticleId IdType="pubmed">26006014</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata S, Tanaka Y. B-cell subsets, signaling and their roles in secretion of autoantibodies. Lupus (2016) 25(8):850&#x2013;6. doi:&#xa0;10.1177/0961203316643172</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316643172</ArticleId><ArticleId IdType="pubmed">27252261</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y. State-of-the-art treatment of systemic lupus erythematosus. Int J Rheum Dis (2020) 23:465&#x2013;71. doi:&#xa0;10.1111/1756-185X.13817</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13817</ArticleId><ArticleId IdType="pmc">PMC7187183</ArticleId><ArticleId IdType="pubmed">32134201</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vollenhoven RF, Askanase AD, Bomback AS, Bruce IN, Carroll A, Dall'Era M, et al. . Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Sci Med (2022) 9(1):e000634. doi:&#xa0;10.1136/lupus-2021-000634</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000634</ArticleId><ArticleId IdType="pmc">PMC8961173</ArticleId><ArticleId IdType="pubmed">35346982</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodnow CC, Sprent J, de St Groth BF, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature (2005) 435:590&#x2013;7. doi:&#xa0;10.1038/nature03724</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03724</ArticleId><ArticleId IdType="pubmed">15931211</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair PA, Nore&#xf1;a LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. . CD19(+)CD24(hi)CD38(hi) b cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity (2010) 32(1):129&#x2013;40. doi:&#xa0;10.1016/j.immuni.2009.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.11.009</ArticleId><ArticleId IdType="pubmed">20079667</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon M, Blair PA, Isenberg DA, Mauri C. A regulatory feedback between plasmacytoid dendritic cells and regulatory b cells is aberrant in systemic lupus erythematosus. Immunity (2016) 44(3):683&#x2013;97. doi:&#xa0;10.1016/j.immuni.2016.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.02.012</ArticleId><ArticleId IdType="pmc">PMC4803914</ArticleId><ArticleId IdType="pubmed">26968426</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernis AB, Ivashkiv LB. '-omics' shed light on b cells in lupus. Nat Immunol (2019) 20(8):946&#x2013;8. doi:&#xa0;10.1038/s41590-019-0446-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0446-6</ArticleId><ArticleId IdType="pubmed">31285628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive b cells. Eur J Immunol (2006) 36(4):810&#x2013;6. doi:&#xa0;10.1002/eji.200535744</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200535744</ArticleId><ArticleId IdType="pubmed">16541472</ArticleId></ArticleIdList></Reference><Reference><Citation>Niiro H, Clark EA. Regulation of b-cell fate by antigen-receptor signals. Nat Rev Immunol (2002) 2(12):945&#x2013;56. doi:&#xa0;10.1038/nri955</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri955</ArticleId><ArticleId IdType="pubmed">12461567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemon P, Renaudineau Y, Debant M, Le Goux N, Mukherjee S, Brooks W, et al. . Calcium signaling: from normal b cell development to tolerance breakdown and autoimmunity. Clin Rev Allergy Immunol (2017) 53(2):141&#x2013;65. doi:&#xa0;10.1007/s12016-017-8607-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-017-8607-6</ArticleId><ArticleId IdType="pubmed">28500564</ArticleId></ArticleIdList></Reference><Reference><Citation>Grammer AC, Fischer R, Lee O, Zhang X, Lipsky PE. Flow cytometric assessment of the signaling status of human b lymphocytes from normal and autoimmune individuals. Arthritis Res Ther (2004) 6:28&#x2013;38. doi:&#xa0;10.1186/ar1155</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar1155</ArticleId><ArticleId IdType="pmc">PMC400425</ArticleId><ArticleId IdType="pubmed">14979930</ArticleId></ArticleIdList></Reference><Reference><Citation>Liossis S, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest (1996) 98:2549&#x2013;57. doi: 10.1172/JCI119073</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI119073</ArticleId><ArticleId IdType="pmc">PMC507712</ArticleId><ArticleId IdType="pubmed">8958217</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay M, Stanevsky A, Wang T, Aranow C, Li M, Koenig S, et al. . Selective dysregulation of the FcgIIB receptor on memory b cells in SLE. J Exp Med (2006) 203:2157&#x2013;64. doi:&#xa0;10.1084/jem.20051503</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20051503</ArticleId><ArticleId IdType="pmc">PMC2118390</ArticleId><ArticleId IdType="pubmed">16923849</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu XN, Ye YX, Niu JW, Li Y, Li X, You X, et al. . Defective PTEN regulation contributes to b cell hyperresponsiveness in systemic lupus erythematosus. Sci Transl Med (2014) 6(246):246ra99. doi:&#xa0;10.1126/scitranslmed.3009131</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3009131</ArticleId><ArticleId IdType="pubmed">25101889</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA. Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in b lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum (2007) 56:291&#x2013;302. doi:&#xa0;10.1002/art.22309</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22309</ArticleId><ArticleId IdType="pubmed">17195233</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi T, Kobayashi T, Kondo J, Takahashi K, Nakamura H, J Suzuki J, et al. . Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem (1991) 266:15790&#x2013;6. doi: 10.1016/S0021-9258(18)98478-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)98478-4</ArticleId><ArticleId IdType="pubmed">1874735</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WS, Leong KP. Tyrosine kinase inhibitors: a new approach for asthma. Biochim Biophys Acta (2004) 1697:53&#x2013;69. doi:&#xa0;10.1016/j.bbapap.2003.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2003.11.013</ArticleId><ArticleId IdType="pubmed">15023350</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaven MA, Baumgartner RA. Downstream signals initiated in mast cells by fc epsilon RI and other receptors. Curr Opin Immunol (1996) 8:766&#x2013;72. doi:&#xa0;10.1016/s0952-7915(96)80002-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0952-7915(96)80002-1</ArticleId><ArticleId IdType="pubmed">8994853</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, et al. . An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum (2008) 58:1433&#x2013;44. doi:&#xa0;10.1002/art.23428</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23428</ArticleId><ArticleId IdType="pubmed">18438845</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum (2010) 62:2086&#x2013;92. doi:&#xa0;10.1002/art.27452</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27452</ArticleId><ArticleId IdType="pmc">PMC2902591</ArticleId><ArticleId IdType="pubmed">20222110</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata S, Yamaoka K, Niiro H, Nakano K, Wang SP, Akashi K, et al. . Amplification of toll-like receptor-mediated signaling through spleen tyrosine kinase in human b-cell activation. J Allergy Clin Immunol (2012) 129:1594&#x2013;601. doi:&#xa0;10.1016/j.jaci.2012.03.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2012.03.014</ArticleId><ArticleId IdType="pubmed">22541243</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata S, Yamaoka K, Niiro H, Jabbarzadeh-Tabrizi S, Wang SP, Kondo M, et al. . Increased syk phosphorylation leads to overexpression of TRAF6 in peripheral b cells of patients with systemic lupus erythematosus. Lupus (2015) 24:695&#x2013;704. doi:&#xa0;10.1177/0961203314560424</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314560424</ArticleId><ArticleId IdType="pubmed">25432781</ArticleId></ArticleIdList></Reference><Reference><Citation>Satterthwaite AB, Li Z, Witte ON. Btk function in b cell development and response. Semin Immunol (1998) 10:309&#x2013;16. doi:&#xa0;10.1006/smim.1998.0123</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/smim.1998.0123</ArticleId><ArticleId IdType="pubmed">9695187</ArticleId></ArticleIdList></Reference><Reference><Citation>Kil LP, de Bruijn MJ, van Nimwegen M, Corneth OB, van Hamburg JP, Dingjan GM, et al. . Btk levels set the threshold for b-cell activation and negative selection of autoreactive b cells in mice. Blood (2012) 119:3744&#x2013;56. doi:&#xa0;10.1182/blood-2011-12-397919</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-12-397919</ArticleId><ArticleId IdType="pubmed">22383797</ArticleId></ArticleIdList></Reference><Reference><Citation>Thien CB, Langdon WY. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol (2001) 2:294&#x2013;307. doi:&#xa0;10.1038/35067100</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35067100</ArticleId><ArticleId IdType="pubmed">11283727</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SP, Iwata S, Nakayamada S, Niiro H, Jabbarzadeh-Tabrizi S, Kondo M, et al. . Amplification of IL-21 signalling pathway through bruton&#x2019;s tyrosine kinase in human b cell activation. Rheumatol (Oxford) (2015) 54:1488&#x2013;97. doi:&#xa0;10.1093/rheumatology/keu532</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu532</ArticleId><ArticleId IdType="pubmed">25724205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, et al. . Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med (2008) 358:900&#x2013;9. doi:&#xa0;10.1056/NEJMoa0707865</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0707865</ArticleId><ArticleId IdType="pubmed">18204098</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozyrev SV, Abelson AK, Wojcik J, Zaghlool A, Linga Reddy MV, Sanchez E, et al. . Functional variants in the b-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet (2008) 40:211&#x2013;6. doi:&#xa0;10.1038/ng.79</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.79</ArticleId><ArticleId IdType="pubmed">18204447</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol (2010) 6(12):683&#x2013;92. doi:&#xa0;10.1038/nrrheum.2010.176</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2010.176</ArticleId><ArticleId IdType="pmc">PMC3135416</ArticleId><ArticleId IdType="pubmed">21060334</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neill LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol (2016) 16:553&#x2013;65. doi:&#xa0;10.1038/nri.2016.70</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.70</ArticleId><ArticleId IdType="pmc">PMC5001910</ArticleId><ArticleId IdType="pubmed">27396447</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercellino I, Sazanov LA. The assembly, regulation and function of the mitochondrial respiratory chain. Nat Rev Mol Cell Biol (2022) 23(2):141&#x2013;61. doi:&#xa0;10.1038/s41580-021-00415-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00415-0</ArticleId><ArticleId IdType="pubmed">34621061</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM, Chi H. Metabolic adaptation of lymphocytes in immunity and disease. Immunity (2022) 55(1):14&#x2013;30. doi:&#xa0;10.1016/j.immuni.2021.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.12.012</ArticleId><ArticleId IdType="pmc">PMC8842882</ArticleId><ArticleId IdType="pubmed">35021054</ArticleId></ArticleIdList></Reference><Reference><Citation>Caro-Maldonado A, Wang R, Nichols AG, Kuraoka M, Milasta S, Sun LD, et al. . Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed b cells. J Immunol (2014) 192:3626&#x2013;36. doi:&#xa0;10.4049/jimmunol.1302062</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302062</ArticleId><ArticleId IdType="pmc">PMC3984038</ArticleId><ArticleId IdType="pubmed">24616478</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. . Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 22:159&#x2013;68. doi:&#xa0;10.1016/j.molcel.2006.03.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2006.03.029</ArticleId><ArticleId IdType="pubmed">16603397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K, Gudapati P, Dragovic S, Spencer C, Joyce S, Killeen N, et al. . Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity (2010) 32:743&#x2013;53. doi:&#xa0;10.1016/j.immuni.2010.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.06.002</ArticleId><ArticleId IdType="pmc">PMC2911434</ArticleId><ArticleId IdType="pubmed">20620941</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al. . The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 12:295&#x2013;303. doi:&#xa0;10.1038/ni.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2005</ArticleId><ArticleId IdType="pmc">PMC3077821</ArticleId><ArticleId IdType="pubmed">21358638</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Qin X, Kurepa Z, Kumar KR, Liu K, Kanta H, et al. . Shared signaling networks active in b cells isolated from genetically distinct mouse models of lupus. J Clin Invest (2007) 117:2186&#x2013;96. doi:&#xa0;10.1172/JCI30398</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI30398</ArticleId><ArticleId IdType="pmc">PMC1913486</ArticleId><ArticleId IdType="pubmed">17641780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Q, Zhang H, Qin J, Xu Z, Gui L, Liu B, et al. . Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-erk 1/2 signaling pathway in normal and neoplastic b-lymphoid cells. Cell Mol Life Sci (2015) 72:4867&#x2013;84. doi:&#xa0;10.1007/s00018-015-1976-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-015-1976-1</ArticleId><ArticleId IdType="pmc">PMC9295025</ArticleId><ArticleId IdType="pubmed">26118661</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K, Heffington L, Jellusova J, Nam KT, Raybuck A, Cho SH, et al. . Requirement for rictor in homeostasis and function of mature b lymphoid cells. Blood (2013) 122:2369&#x2013;79. doi:&#xa0;10.1182/blood-2013-01-477505</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-01-477505</ArticleId><ArticleId IdType="pmc">PMC3790507</ArticleId><ArticleId IdType="pubmed">23958952</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Lazorchak AS, Ouyang X, Zhang H, Liu H, Arojo OA, et al. . Sin1/mTORC2 regulate b cell growth and metabolism by activating mTORC1 and myc. Cell Mol Immunol (2019) 16:757&#x2013;69. doi:&#xa0;10.1038/s41423-018-0185-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-018-0185-x</ArticleId><ArticleId IdType="pmc">PMC6804816</ArticleId><ArticleId IdType="pubmed">30705387</ArticleId></ArticleIdList></Reference><Reference><Citation>Omori SA, Cato MH, Anzelon-Mills A, Puri KD, Shapiro-Shelef M, Calame K, et al. . Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity (2006) 25:545&#x2013;57. doi:&#xa0;10.1016/j.immuni.2006.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.08.015</ArticleId><ArticleId IdType="pubmed">17000121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodson DJ, Turner M. The role of PI3K signalling in the b cell response to antigen. Adv Exp Med Biol (2009) 633:43&#x2013;53. doi:&#xa0;10.1007/978-0-387-79311-5_5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-0-387-79311-5_5</ArticleId><ArticleId IdType="pubmed">19209680</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Getahun A, Chen X, Dollin Y, Cambier JC, Wang JH. Imbalanced PTEN and PI3K signaling impairs class switch recombination. J Immunol (2015) 195:5461&#x2013;71. doi:&#xa0;10.4049/jimmunol.1501375</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1501375</ArticleId><ArticleId IdType="pmc">PMC4655169</ArticleId><ArticleId IdType="pubmed">26500350</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu H, Mallya S, Nguyen P, Mai A, Jackson LV, Winkler DG, et al. . The selective phosphoinoside-3-Kinase p110&#x3b4; inhibitor IPI-3063 potently suppresses b cell survival, proliferation, and differentiation. Front Immunol (2017) 8:747. doi:&#xa0;10.3389/fimmu.2017.00747</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00747</ArticleId><ArticleId IdType="pmc">PMC5491903</ArticleId><ArticleId IdType="pubmed">28713374</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu H, Jackson LV, Kwon Ik Oh KI, Mai A, Ronai ZA, Ruggero D, et al. . The mTORC1/4E-BP/eIF4E axis promotes antibody class switching in b lymphocytes. J Immunol (2019) 202(2):579&#x2013;90. doi:&#xa0;10.4049/jimmunol.1800602</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1800602</ArticleId><ArticleId IdType="pmc">PMC6324996</ArticleId><ArticleId IdType="pubmed">30530594</ArticleId></ArticleIdList></Reference><Reference><Citation>Limon JJ, So L, Jellbauer S, Chiu H, Corado J, SM S, et al. . mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci USA (2014) 111:E5076&#x2013;85. doi:&#xa0;10.4049/jimmunol.1800602</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1800602</ArticleId><ArticleId IdType="pmc">PMC4250172</ArticleId><ArticleId IdType="pubmed">25385646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L, Anne D. BAFF and selection of autoreactive b cells. Trends Immunol (2011) 32:388&#x2013;94. doi:&#xa0;10.1016/j.it.2011.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2011.06.004</ArticleId><ArticleId IdType="pmc">PMC3151317</ArticleId><ArticleId IdType="pubmed">21752714</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayed M, Gordon C. Novel treatments for systemic lupus erythematosus. Curr Opin Invest Drugs (2010) 11:1256&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">21157645</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell (2012) 149(2):274&#x2013;93. doi:&#xa0;10.1016/j.cell.2012.03.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.03.017</ArticleId><ArticleId IdType="pmc">PMC3331679</ArticleId><ArticleId IdType="pubmed">22500797</ArticleId></ArticleIdList></Reference><Reference><Citation>Torigoe M, Iwata S, Nakayamada S, Sakata K, Zhang M, Hajime M, et al. . Metabolic reprogramming commits differentiation of human CD27 + IgD + b cells to plasmablasts or CD27-IgD&#x2013; cells. J Immunol (2017) 199:425&#x2013;34. doi:&#xa0;10.4049/jimmunol.1601908</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601908</ArticleId><ArticleId IdType="pubmed">28626065</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Iwata S, Hajime M, Ohkubo N, Todoroki Y, Miyata H, et al. . Methionine commits cells to differentiate into plasmablasts through epigenetic regulation of BTB and CNC homolog 2 by the methyltransferase EZH2. Arthritis Rheumatol (2020) 72:1143&#x2013;53. doi:&#xa0;10.1002/art.41208</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41208</ArticleId><ArticleId IdType="pubmed">31961063</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfson RL, Sabatini DM. The dawn of the age of amino acid sensors for the mTORC1 pathway. Cell Metab (2017) 26:301&#x2013;9. doi:&#xa0;10.1016/j.cmet.2017.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2017.07.001</ArticleId><ArticleId IdType="pmc">PMC5560103</ArticleId><ArticleId IdType="pubmed">28768171</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BC, Kaya A, Ma S, Kim G, Gerashchenko MV, Yim SH, et al. . Methionine restriction extends lifespan of drosophila melanogaster under conditions of low amino-acid status. Nat Commun (2014) 5:3592. doi:&#xa0;10.1038/ncomms4592</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4592</ArticleId><ArticleId IdType="pmc">PMC4350766</ArticleId><ArticleId IdType="pubmed">24710037</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesin L, Ersching J, Victora GD. Germinal center b cell dynamics. Immunity (2016) 45:471&#x2013;82. doi:&#xa0;10.1016/j.immuni.2016.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.09.001</ArticleId><ArticleId IdType="pmc">PMC5123673</ArticleId><ArticleId IdType="pubmed">27653600</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H, Muto A, Shima H, Katoh Y, Sax N, Tajima S, et al. . Epigenetic regulation of the blimp-1 gene (Prdm1) in b cells involves Bach2 and histone deacetylase 3. J Biol Chem (2016) 291:6316&#x2013;30. doi:&#xa0;10.1074/jbc.M116.713842</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.713842</ArticleId><ArticleId IdType="pmc">PMC4813568</ArticleId><ArticleId IdType="pubmed">26786103</ArticleId></ArticleIdList></Reference><Reference><Citation>Dann SG, Ryskin M, Barsotti AM, Golas J, Shi C, Miranda M, et al. . Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2. EMBO J (2015) 34:1773&#x2013;85. doi:&#xa0;10.15252/embj.201488166</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201488166</ArticleId><ArticleId IdType="pmc">PMC4516430</ArticleId><ArticleId IdType="pubmed">25979827</ArticleId></ArticleIdList></Reference><Reference><Citation>Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. . High-resolution profiling of histone methylations in the human genome. Cell (2007) 129(4):823&#x2013;37. doi: 10.1016/j.cell.2007.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.05.009</ArticleId><ArticleId IdType="pubmed">17512414</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita M, Gravel SP, Hulea L, Larsson O, Pollak M, St-Pierre J, et al. . mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle (2015) 14(4):473&#x2013;80. doi:&#xa0;10.4161/15384101.2014.991572</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/15384101.2014.991572</ArticleId><ArticleId IdType="pmc">PMC4615141</ArticleId><ArticleId IdType="pubmed">25590164</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita M, Gravel SP, Ch&#xe9;nard V, Sikstr&#xf6;m K, Zheng L, Alain T, et al. . mTORC1 controls mitochondrial activity and biogenesis through 4E- BP-dependent translational regulation. Cell Metab (2013) 18:698&#x2013;711. doi:&#xa0;10.1016/j.cmet.2013.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2013.10.001</ArticleId><ArticleId IdType="pubmed">24206664</ArticleId></ArticleIdList></Reference><Reference><Citation>Noji H, Yasuda R, Yoshida M, Kinosita K, Jr. Direct observation of the rotation of F1-ATPase. Nature (1997) 386:299&#x2013;302. doi:&#xa0;10.1038/386299a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/386299a0</ArticleId><ArticleId IdType="pubmed">9069291</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MP. How mitochondria produce reactive oxygen species. Biochem J (2009) 417:1&#x2013;13. doi:&#xa0;10.1042/BJ20081386</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20081386</ArticleId><ArticleId IdType="pmc">PMC2605959</ArticleId><ArticleId IdType="pubmed">19061483</ArticleId></ArticleIdList></Reference><Reference><Citation>Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK, et al. . Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus- like disease. Nat Med (2016) 22:146&#x2013;53. doi:&#xa0;10.1038/nm.4027</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4027</ArticleId><ArticleId IdType="pmc">PMC4742415</ArticleId><ArticleId IdType="pubmed">26779811</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorobjeva N, Prikhodko A, Galkin I, Pletjushkina O, Zinovkin R, Sud'ina G, et al. . Mitochondrial reactive oxygen species are involved in chemoattractant- induced oxidative burst and degranulation of human neutrophils in vitro . Eur J Cell Biol (2017) 96:254&#x2013;65. doi:&#xa0;10.1016/j.ejcb.2017.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcb.2017.03.003</ArticleId><ArticleId IdType="pubmed">28325500</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset S, Emre Y, Join-Lambert O, Hurtaud C, Ricquier D, Cassard-Doulcier AM. The uncoupling protein 2 modulates the cytokine balance in innate immunity. Cytokine (2006) 35:135&#x2013;42. doi:&#xa0;10.1016/j.cyto.2006.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2006.07.012</ArticleId><ArticleId IdType="pubmed">16971137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Cai F, Chen X, Luo M, Hu L, Lu Y. The role of mitochondria- derived reactive oxygen species in hyperthermia- induced platelet apoptosis. PloS One (2013) 8:e75044. doi:&#xa0;10.1371/journal.pone.0075044</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075044</ArticleId><ArticleId IdType="pmc">PMC3762754</ArticleId><ArticleId IdType="pubmed">24023970</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickinson BC, Chang CJ. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat Chem Biol (2011) 7:504&#x2013;11. doi:&#xa0;10.1038/nchembio.607</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.607</ArticleId><ArticleId IdType="pmc">PMC3390228</ArticleId><ArticleId IdType="pubmed">21769097</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan PE, Sturgess AD, Davies MJ. Evidence for chronically elevated serum protein oxidation in systemic lupus erythematosus patients. Free Radic Res (2009) 43:117&#x2013;27. doi:&#xa0;10.1080/10715760802623896</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10715760802623896</ArticleId><ArticleId IdType="pubmed">19096973</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Houten B, Woshner V, Santos JH. Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair (Amst) (2006) 5(2):145&#x2013;52. doi:&#xa0;10.1016/j.dnarep.2005.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2005.03.002</ArticleId><ArticleId IdType="pubmed">15878696</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker YLC, Duvvuri B, Fortin PR, Lood C, Boilard E. The role of mitochondria in rheumatic diseases. Nat Rev Rheumatol (2022) 18(11):621&#x2013;40. doi:&#xa0;10.1038/s41584-022-00834-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-022-00834-z</ArticleId><ArticleId IdType="pubmed">36175664</ArticleId></ArticleIdList></Reference><Reference><Citation>Buang N, Tapeng L, Gray V, Sardini A, Whilding C, Lightstone L, et al. . Type I interferons affect the metabolic fitness of CD8+ T cells from patients with systemic lupus erythematosus. Nat Commun (2021) 12:1980. doi:&#xa0;10.1038/s41467-021-22312-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22312-y</ArticleId><ArticleId IdType="pmc">PMC8012390</ArticleId><ArticleId IdType="pubmed">33790300</ArticleId></ArticleIdList></Reference><Reference><Citation>Caielli S, Athale S, Domic B, Murat E, Chandra M, Banchereau R, et al. . Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus. J Exp Med (2016) 213:697&#x2013;713. doi:&#xa0;10.1084/jem.20151876</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151876</ArticleId><ArticleId IdType="pmc">PMC4854735</ArticleId><ArticleId IdType="pubmed">27091841</ArticleId></ArticleIdList></Reference><Reference><Citation>Caielli S, Veiga DT, Balasubramanian P, Athale S, Domic B, Murat E, et al. . A CD4+ T cell population expanded in lupus blood provides b cell help through interleukin-10 and succinate. Nat Med (2019) 25:75&#x2013;81. doi:&#xa0;10.1038/s41591-018-0254-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0254-9</ArticleId><ArticleId IdType="pmc">PMC6325012</ArticleId><ArticleId IdType="pubmed">30478422</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumikawa M, Iwata S, Zhang M, Miyata H, Ueno M, Todoroki Y, et al. . An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. Rheumatol (Oxford) (2022) 61(7):3049&#x2013;59. doi:&#xa0;10.1093/rheumatology/keab824</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab824</ArticleId><ArticleId IdType="pubmed">34730825</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeshima Y, Iwasaki Y, Nakano M, Narushima Y, Ota M, Nagafuchi Y, et al. . Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to b cell functions and organ damage of lupus. Ann Rheum Dis (2022) 81(6):845&#x2013;53. doi:&#xa0;10.1136/annrheumdis-2021-221464</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221464</ArticleId><ArticleId IdType="pubmed">35236659</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters LR, Ahsan FM, Wolf DM, Shirihai O, Teitell MA. Initial b cell activation induces metabolic reprogramming and mitochondrial remodeling. iScience (2018) 5:99&#x2013;109. doi:&#xa0;10.1016/j.isci.2018.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2018.07.005</ArticleId><ArticleId IdType="pmc">PMC6123864</ArticleId><ArticleId IdType="pubmed">30240649</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford J, Cohen HJ. The essential role of l-glutamine in lymphocyte differentiation in vitro . J Cell Physiol (1985) 124(2):275&#x2013;82. doi:&#xa0;10.1002/jcp.1041240216</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.1041240216</ArticleId><ArticleId IdType="pubmed">4044655</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Autr&#xe9;aux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol (2007) 8(10):813&#x2013;24. doi:&#xa0;10.1038/nrm2256</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2256</ArticleId><ArticleId IdType="pubmed">17848967</ArticleId></ArticleIdList></Reference><Reference><Citation>Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol (2002) 3:1129&#x2013;34. doi:&#xa0;10.1038/ni1202-1129</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1202-1129</ArticleId><ArticleId IdType="pubmed">12447370</ArticleId></ArticleIdList></Reference><Reference><Citation>Capasso M, Bhamrah MK, Henley T, Boyd RS, Langlais C, Cain K, et al. . HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nat Immunol (2010) 11:265&#x2013;72. doi:&#xa0;10.1038/ni.1843</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1843</ArticleId><ArticleId IdType="pmc">PMC3030552</ArticleId><ArticleId IdType="pubmed">20139987</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams WC, Chen YH, Kratchmarov R, Yen B, Nish SA, Lin WW, et al. . Anabolism associated mitochondrial stasis driving lymphocyte differentiation over selfrenewal. Cell Rep (2016) 17:3142&#x2013;52. doi:&#xa0;10.1016/j.celrep.2016.11.065</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.11.065</ArticleId><ArticleId IdType="pmc">PMC5189677</ArticleId><ArticleId IdType="pubmed">28009285</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang G, Bi Y, Jiang Z, Wang X. Inhibition of glutaminolysis ameliorates lupus by regulating T and b cell subsets and downregulating the mTOR/p70S6K/4EBP1 and NLRP3/captase-1/IL-1&#x3b2; pathways in MRL/lpr mice. Int Immunopharmacol (2022) 112:109133. doi:&#xa0;10.1016/j.intimp.2022.109133</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.109133</ArticleId><ArticleId IdType="pubmed">36113317</ArticleId></ArticleIdList></Reference><Reference><Citation>Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab (2014) 20:953&#x2013;66. doi:&#xa0;10.1016/j.cmet.2014.09.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2014.09.018</ArticleId><ArticleId IdType="pubmed">25456737</ArticleId></ArticleIdList></Reference><Reference><Citation>Batandier C, Guigas B, Detaille D, El-Mir MY, Fontaine E, Rigoulet M, et al. . The ROS production induced by a reverse electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr (2006) 38:33e42. doi:&#xa0;10.1007/s10863-006-9003-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10863-006-9003-8</ArticleId><ArticleId IdType="pubmed">16732470</ArticleId></ArticleIdList></Reference><Reference><Citation>Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia (2017) 60(9):1577&#x2013;85. doi:&#xa0;10.1007/s00125-017-4342-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4342-z</ArticleId><ArticleId IdType="pmc">PMC5552828</ArticleId><ArticleId IdType="pubmed">28776086</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharer CD, Blalock EL, Mi T, Barwick BG, Jenks SA, Deguchi T, et al. . Epigenetic programming underpins b cell dysfunction in human SLE. Nat Immunol (2019) 20(8):1071&#x2013;82. doi:&#xa0;10.1038/s41590-019-0419-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0419-9</ArticleId><ArticleId IdType="pmc">PMC6642679</ArticleId><ArticleId IdType="pubmed">31263277</ArticleId></ArticleIdList></Reference><Reference><Citation>Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, et al. . The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol (2019) 20(7):902&#x2013;14. doi:&#xa0;10.1038/s41590-019-0398-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0398-x</ArticleId><ArticleId IdType="pmc">PMC6726437</ArticleId><ArticleId IdType="pubmed">31209404</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Fu Q, Guo Q, Chen S, Goswami S, Sun S, et al. . Lupus-associated atypical memory b cells are mTORC1-hyperactivated and functionally dysregulated. Ann Rheum Dis (2019) 78(8):1090&#x2013;100. doi:&#xa0;10.1136/annrheumdis-2019-215039</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215039</ArticleId><ArticleId IdType="pmc">PMC6691860</ArticleId><ArticleId IdType="pubmed">31142473</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf SD, Dittel BN, Hardardottir F, Janeway CA., Jr. Experimental autoimmune encephalomyelitis induction in genetically b cell-deficient mice. J Exp Med (1996) 184:2271&#x2013;8. doi:&#xa0;10.1084/jem.184.6.2271</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.184.6.2271</ArticleId><ArticleId IdType="pmc">PMC2196394</ArticleId><ArticleId IdType="pubmed">8976182</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauri C, Menon M. Human regulatory b cells in health and disease: therapeutic potential. J Clin Invest (2017) 127(3):772&#x2013;9. doi:&#xa0;10.1172/JCI85113</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI85113</ArticleId><ArticleId IdType="pmc">PMC5330739</ArticleId><ArticleId IdType="pubmed">28248202</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto M, Baba A, Yokota T, Nishikawa H, Ohkawa Y, Kayama H, et al. . Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. Imunity (2014) 41(6):1040&#x2013;51. doi:&#xa0;10.1016/j.immuni.2014.10.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2014.10.016</ArticleId><ArticleId IdType="pubmed">25484301</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto M, Fujii Y, Baba A, Hikida M, Kurosaki T, Baba Y. The calcium sensors STIM1 and STIM2 control b cell regulatory function through interleukin-10 production. Immunity (2011) 34(5):703&#x2013;14. doi:&#xa0;10.1016/j.immuni.2011.03.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.03.016</ArticleId><ArticleId IdType="pubmed">21530328</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L. AHR function in lymphocytes: emerging concepts. Trends Immunol (2016) 37(1):17&#x2013;31. doi:&#xa0;10.1016/j.it.2015.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2015.11.007</ArticleId><ArticleId IdType="pmc">PMC4707131</ArticleId><ArticleId IdType="pubmed">26700314</ArticleId></ArticleIdList></Reference><Reference><Citation>Piper CJM, Rosser EC, Oleinika K, Nistala K, Krausgruber T, Rendeiro AF, et al. . Aryl hydrocarbon receptor contributes to the transcriptional program of IL-10-Producing regulatory b cells. Cell Rep (2019) 29(7):1878&#x2013;92 e7. doi:&#xa0;10.1016/j.celrep.2019.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.10.018</ArticleId><ArticleId IdType="pmc">PMC6856759</ArticleId><ArticleId IdType="pubmed">31722204</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosser EC, Piper CJM, Matei DE, Blair PA, Rendeiro AF, Orford M, et al. . Microbiota-derived metabolites suppress arthritis by amplifying aryl-hydrocarbon receptor activation in regulatory b cells. Cell Metab (2020) 31(4):837&#x2013;51 e10. doi:&#xa0;10.1016/j.cmet.2020.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.03.003</ArticleId><ArticleId IdType="pmc">PMC7156916</ArticleId><ArticleId IdType="pubmed">32213346</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng X, Gr&#xf6;tsch B, Luo Y, Knaup KX, Wiesener MS, Chen XX, et al. . Hypoxia-inducible factor-1a is a critical transcription factor for IL-10-producing b cells in autoimmune disease. Nat Commun (2018) 9:251. doi:&#xa0;10.1038/s41467-017-02683-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02683-x</ArticleId><ArticleId IdType="pmc">PMC5772476</ArticleId><ArticleId IdType="pubmed">29343683</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra S&#xe1;nchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol (2022) 18(3):146&#x2013;57. doi:&#xa0;10.1038/s41584-021-00739-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00739-3</ArticleId><ArticleId IdType="pubmed">35039665</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackensen A, M&#xfc;ller F, Mougiakakos D, B&#xf6;ltz S, Wilhelm A, Aigner M, et al. . Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med (2022) 28(10):2124&#x2013;32. doi:&#xa0;10.1038/s41591-022-02017-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02017-5</ArticleId><ArticleId IdType="pubmed">36109639</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson P, Wallin P, Sjowall C. Clinical experience of sirolimus regarding efficacy and safety in systemic lupus erythematosus. Front Pharmacol (2019) 10:82. doi:&#xa0;10.3389/fphar.2019.00082</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00082</ArticleId><ArticleId IdType="pmc">PMC6372521</ArticleId><ArticleId IdType="pubmed">30787878</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Chan CCY, Cheung KF, Chau MKM, Yap DYH, Ma MKM, et al. . Effect of mycophenolate andrapamycin on renal fibrosis in lupus nephritis. Clin Sci (Lond) (2019) 133:1721&#x2013;44. doi:&#xa0;10.1042/CS20190536</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20190536</ArticleId><ArticleId IdType="pubmed">31358596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai ZW, Kelly R, Winans T, Marchena I, Shadakshari A, Yu J, et al. . Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet (2018) 391:1186 e96. doi: 10.1016/S0140-6736(18)30485-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30485-9</ArticleId><ArticleId IdType="pmc">PMC5891154</ArticleId><ArticleId IdType="pubmed">29551338</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li T, Chen S, Gu Y, Ye S. Neutrophil extracellular trap mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin. Arthritis Rheum (2015) 67:3190 e200. doi:&#xa0;10.1002/art.39296</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39296</ArticleId><ArticleId IdType="pubmed">26245802</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun F, Wang HJ, Liu Z, Geng S, Wang HT, Wang X, et al. . Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Rheumatol (2020) 2:e210&#x2013;6. doi:&#xa0;10.1016/S2665-9913(20)30004-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30004-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun F, Geng S, Wang H, Wang H, Liu Z, Wang X, et al. . Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials. Lupus Sci Med (2020) 7(1):e000429. doi:&#xa0;10.1136/lupus-2020-000429</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000429</ArticleId><ArticleId IdType="pmc">PMC7583791</ArticleId><ArticleId IdType="pubmed">33093216</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornaby C, Elshikha AS, Teng X, Choi SC, Scindia Y, Davidson A, et al. . Efficacy of the combination of metformin and CTLA4Ig in the (NZB &#xd7; NZW)F1 mouse model of lupus nephritis. Immunohorizons (2020) 4:319&#x2013;31. doi:&#xa0;10.4049/immunohorizons.2000033</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.2000033</ArticleId><ArticleId IdType="pubmed">32540987</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>